---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-011767"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:14:55.244121+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY

## Summary
- Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.
- GAAP net loss $4.4M ($0.11 loss per share); adjusted loss $0.08 per share; adjusted EBITDA $1.3M vs -$3.6M a year ago.
- FY2025 guidance raised: net sales $285-288M, Med Tech growth 14-16%, gross margin 53-54%, adjusted EBITDA $4-5M, adjusted EPS loss $(0.31)-(0.34).
- Received FDA 510(k) clearance for NanoKnife System for prostate tissue ablation; initiated AMBITION BTK RCT for Auryon.
- Secured $25M revolver commitment from J.P. Morgan for working capital flexibility; expects positive operating cash flow in Q4.

## SEC filing metadata
- accession: 0001140361-25-011767
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036125011767/0001140361-25-011767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036125011767/ef20046769_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-011767
- JSON: https://secwatch.observer/filing/0001140361-25-011767.json
- Plain text: https://secwatch.observer/filing/0001140361-25-011767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.